Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 AIR001 dose-ranging study in WHO Group 1 pulmonary arterial hypertension
2012-000166-37Phase 2Terminated
- Sponsor
- Aires Pharmaceuticals, Inc.
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of inhaled nitrite in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Aires Pharmaceuticals, Inc. Primary endpoint: Change in pulmonary vascular resistance from baseline to Week 16. Started Nov 2012; status: terminated.
02
Drugs
inhaled nitrite
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2012-000166-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000166-37.